RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 201–300 of 1,003
Kras as a key oncogene and therapeutic target in pancreatic cancer
Collins, M. A., & di Magliano, M. P. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00407 · Cited by 135
“…(Almoguera et al., 1988; Smit et al., 1988); the most common mutation is one amino-acid substitution in position 12 of the Kras protein, leading to a glycine (G) to aspartic acid (D) substitution, although other variants, such as G to V are also common (for review see Pylayeva-Gupta et al., 2011).”
BackgroundGenotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M. W., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 112
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., Almada, L. L., Yurcheko, A., Padioleau, I., Alver, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23186-w · Cited by 104
Shern, J. F., Yohe, M. E., & Khan, J. I. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2015013800 · Cited by 114
RAS proto-oncogene in medullary thyroid carcinoma
Moura, M. M., Cavaco, B. M., & Leite, V. A. P. H. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0070 · Cited by 119
“The major effect of the most common somatic mutations present in the oncogenic variants of RAS alleles is the maintenance of RAS in the GTP-bound state, with the consequent constant activation of a variety of RAS-dependent downstream effector pathways (Pylayeva-Gupta et al. 2011).”
BackgroundRadiation-induced senescence: therapeutic opportunities
Kim, J. H., Brown, S. L., & Gordon, M. N. (2023) · Radiation Oncology · doi:10.1186/s13014-022-02184-2 · Cited by 119
“RAS is a GTPase that is frequently mutated in cancer and that affects a variety of cancerdriving processes [17].”
BackgroundFundamental Limits to Cellular Sensing
ten Wolde, P. R., Becker, N. B., Ouldridge, T. E., & Mugler, A. (2016) · Journal of Statistical Physics · doi:10.1007/s10955-015-1440-5 · Cited by 133
“And many cellular signaling pathways, including two-component systems in bacteria [74], GTP-ase cycles as in the Ras system [63], phosphorylation cycles as in MAPK cascades [19], are driven out of thermal equilibrium via the turnover of fuel.”
BackgroundSmall G Proteins in the Cardiovascular System: Physiological and Pathological Aspects
Loirand, G., Sauzeau, V., & Pacaud, P. (2013) · Physiological Reviews · doi:10.1152/physrev.00021.2012 · Cited by 103
Hu, H., Cheng, R., Wang, Y., Wang, X., Wu, J., Kong, Y., Zhan, S., Zhou, Z., Zhu, H., Yu, R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci153470 · Cited by 119
“Mutations in the KRAS gene are the most common drivers of tumor development across a spectrum of human cancers, such as cancers of the lung, colon, and pancreas (1-3).”
BackgroundGrass, G. D., Tolliver, L. B., Bratoeva, M., & Toole, B. P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497685 · Cited by 111
Kumar, S., & Agnihotri, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.182 · Cited by 113
Rotow, J. K., Gui, P., Wu, W., Raymond, V. M., Lanman, R. B., Kaye, F. J., Peled, N., de la Cruz, F. F., Nadres, B., Corcoran, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1667 · Cited by 113
“We also describe the spectrum and relative frequencies of newly detectable genomic alterations followingMET TKI treatment as measured by cfDNA, which included alterations within the RAS– MAPK pathway or within RTKs upstream of the RAS–MAPK pathway (49) in two thirds of patients.”
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110
“Oncogenic mutations occur most frequently in codons 12, 13, 61, and 146, and the resulting proteins are resistant to GAP-mediated guanosine triphosphate (GTP) hydrolysis, rendering them constitutively Cell Re active (Cox and Der, 2010; Pylayeva-Gupta et al., 2011).”
Ras signaling through RASSF proteins
Donninger, H., Schmidt, M., Mezzanotte-Sharpe, J., Barnoud, T., & Clark, G. J. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.007 · Cited by 115
Terrell, E. M., Durrant, D. E., Ritt, D. A., Sealover, N. E., Sheffels, E., Spencer-Smith, R., Esposito, D., Zhou, Y., Hancock, J. F., Kortum, R. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.004 · Cited by 114
“Graphical Abstract INTRODUCTION Ras proteins are membrane-associated, small GTPases that function to transmit a multitude of cellular signals (Pylayeva-Gupta et al., 2011).”
BackgroundOncogenic KRAS: Signaling and Drug Resistance
Kim, H. J., Lee, H. N., Jeong, M. S., & Jang, S. B. (2021) · Cancers · doi:10.3390/cancers13225599 · Cited by 119
Ntai, I., Fornelli, L., DeHart, C. J., Hutton, J. E., Doubleday, P. F., LeDuc, R. D., van Nispen, A. J., Fellers, R. T., Whiteley, G., Boja, E. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716122115 · Cited by 108
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers
Seguin, L., Camargo, M. F., Wettersten, H. I., Kato, S., Desgrosellier, J. S., von Schalscha, T., Elliott, K. C., Cosset, E., Lesperance, J., Weis, S. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0539 · Cited by 102
“25–30% of non-small cell lung cancers express mutant KRAS [16], yet only about half of these are addicted or depend on KRAS for their survival [17], thus representing an interesting model to investigate the molecular basis for KRAS addiction.”
BackgroundThe impact of oncogenic RAS on redox balance and implications for cancer development
Lim, J. K. M., & Leprivier, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2192-y · Cited by 115
The molecular genetics of RASopathies : An update on novel disease genes and new disorders
Tartaglia, M., Aoki, Y., & Gelb, B. D. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32012 · Cited by 116
Duldulao, M. P., Lee, W., Nelson, R. A., Li, W., Chen, Z., Kim, J., & Garcia-Aguilar, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2910-0 · Cited by 104
“Persistent activation of KRAS affects numerous downstream pathways that play a role in cancer progression.(21) Several studies suggest that the specific location of KRAS mutation within the gene can affect different downstream pathways, which ultimately could affect tumor response to therapy.”
Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer
Xing, M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0559-9 · Cited by 107
“The RAS oncogene plays a fundamental role in human tumorigenesis [1].”
BackgroundKRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01732-6 · Cited by 101
Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
Cisowski, J., Sayin, V. I., Liu, M., Karlsson, C., & Bergo, M. O. (2016) · Oncogene · doi:10.1038/onc.2015.186 · Cited by 104
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 93
OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination
Baietti, M. F., Šimíček, M., Asbagh, L. A., Radaelli, E., Lievens, S., Crowther, J., Steklov, M. Y., Aushev, V. N., Martínez‐García, D., Tavernier, J. H., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505972 · Cited by 111
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
Li, C., Vides, A., Kim, D., Xue, J. Y., Zhao, Y., & Lito, P. (2021) · Science · doi:10.1126/science.abf1730 · Cited by 103
Drosten, M., Sum, E. Y. M., Lechuga, C. G., Simón-Carrasco, L., Jacob, H. K. C., García-Medina, R., Huang, S., Beijersbergen, R. L., Bernards, R., & Barbacid, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417549111 · Cited by 103
“T RAS genes have been extensively studied due to their key role in mediating mitogenic signaling as well as their high prevalence in human cancers, including those cancers with poor survival rates, such as lung adenocarcinoma, colorectal carcinoma, and pancreatic ductal adenocarcinoma (1, 2).”
BackgroundRegulation of TOR by small GTPases
Durán, R. V., & Hall, M. N. (2012) · The EMBO Reports · doi:10.1038/embor.2011.257 · Cited by 102
“Aberrant activation of GTPases, including Ras, Rho, Rab or Ran GTPases, promotes cell transformation and cancer (Agola et al , 2011; Ly et al , 2010; Pylayeva-Gupta et al , 2011), in some cases by acting in the mTOR pathway.”
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan, N., Boyer, J. L., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1762 · Cited by 102
“Unlike in HRas and NRas, KRas Q61 oncogenic mutations are very rare (7).”
The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling
Chakraborty, A., Diefenbacher, M. E., Mylona, A., Kassel, O., & Behrens, A. (2015) · Nature Communications · doi:10.1038/ncomms7782 · Cited by 107
“Oligonucleotide sequences (sense strand) were: siTrim7 (1): 5′-CGGAAAAGAAGGAGAGCAA-3′; siTrim7 3′-UTR (2): 5′GCAUCACGGCUCUCCAGCA-3′; siMSK1 (1): 5′-GCAGAAGAGUUCACAGAAA-3′; siMSK1 (2): 5′-GGAAAUAACAGCUCUGAAA-3′; siMSK2 (1): 5′CGGCCGAGAUCAUGUGCAA-3′; siMSK2 (2): 5′-GCCGAGAUCAUGUGCAAAA-3′.”
SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a
Jing, H., Zhang, X., Wisner, S., Chen, X., Spiegelman, N. A., Linder, M. E., & Lin, H. (2017) · eLife · doi:10.7554/elife.32436 · Cited by 102
“Since suppression of apoptosis is linked to Rasinduced transformation (Pylayeva-Gupta et al., 2011), it is plausible that A-Raf and Aif are involved in the regulation of K-Ras4a transformation activity by lysine fatty acylation.”
BackgroundTsujita, K., Satow, R., Asada, S., Nakamura, Y., Arnes, L., Sako, K., Fujita, Y., Fukami, K., & Itoh, T. (2021) · Nature Communications · doi:10.1038/s41467-021-26156-4 · Cited by 104
Jiang, W., Liu, N., Chen, X.-Z., Sun, Y. H., Li, B., Ren, X., Qin, W.-F., Jiang, N., Xu, Y.-F., Li, Y.-Q., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0260 · Cited by 104
Gao, S., Soares, F., Wang, S., Wong, C. C., Chen, H., Yang, Z., Liu, W., Go, M. Y. Y., Ahmed, M., Zeng, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01882-7 · Cited by 97
Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Acquaviva, J., Smith, D. L., Sang, J., Friedland, J. C., He, S., Sequeira, M., Zhang, C., Wada, Y., & Proia, D. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0615 · Cited by 96
“ly observed in KRAS, predominantly arising as single amino acid substitutions at residues G12, G13, or Q61 (9).”
BackgroundInfluentialMasgras, I., Ciscato, F., Brunati, A. M., Tibaldi, E. V., Indraccolo, S., Curtarello, M., Chiara, F., Cannino, G., Papaleo, E., Lambrughi, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.056 · Cited by 103
Molecular genetics and cellular events of K-Ras-driven tumorigenesis
Jinesh, G. G., Sambandam, V., Vijayaraghavan, S., Balaji, K., & Mukherjee, S. (2017) · Oncogene · doi:10.1038/onc.2017.377 · Cited by 108
Digging deeper through glucose metabolism and its regulators in cancer and metastasis
Ghanavat, M., Shahrouzian, M., Zayeri, Z. D., Banihashemi, S., Kazemi, S. M., & Saki, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118603 · Cited by 105
Chen, Z., Huang, Y., Hu, Z., Zhao, M., Li, M., Bi, G., Zheng, Y., Liang, J., Lu, T., Jiang, W., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.350 · Cited by 107
Lochhead, P. J., & Chan, A. T. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.037 · Cited by 109
Iatrogenic endometriosis harbors somatic cancer-driver mutations
Lac, V, Verhoef, L., Aguirre-Hernandez, R., Nazeran, T. M., Tessier-Cloutier, B., Praetorius, T., Orr, N. L., Noga, H., Lum, A., Khattra, J., et al. (2019) · Human Reproduction · doi:10.1093/humrep/dey332 · Cited by 99
Chen, W.-Y., Liu, S.-Y., Chang, Y.-S., Juan Yin, J., Yeh, H.-L., Mouhieddine, T. H., Hadadeh, O., Abou-Kheir, W., & Liu, Y.-N. (2015) · Oncotarget · doi:10.18632/oncotarget.2690 · Cited by 100
“The presence of Ras mutations as a cause of resistance to apoptosis in various cancers brought a major challenge in the treatment of metastasis [25].”
BackgroundStructural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Guillard, S., Kolasinska-Zwierz, P., Debreczeni, J., Breed, J., Zhang, J., Bery, N., Marwood, R., Tart, J., Overman, R., Stocki, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16111 · Cited by 102
Gu, L., Deng, Z. J., Roy, S., & Hammond, P. T. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2186 · Cited by 101
“However, small-molecule inhibitors and drugs to restore p53 function remain elusive (16, 17).”
DNA replication stress: oncogenes in the spotlight
Primo, L. M. F., & Teixeira, L. K. (2020) · Genetics and Molecular Biology · doi:10.1590/1678-4685gmb-2019-0138 · Cited by 102
The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis
Zinatizadeh, M. R., Miri, S. R., Zarandi, P. K., Chalbatani, G. M., Rapôso, C., Mirzaei, H. R., Akbari, M. E., & Mahmoodzadeh, H. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2019.11.003 · Cited by 94
“The most common oncogenic pathway in different types of tumor is the RAS transduction pathway and also the active mutations responsible for the direct growth and survival signals.(1,92,93) Mutation in all RAS isoforms (K-RAS, H-RAS, and N-RAS) enhances the active form of the protein.”
BackgroundGrewal, S. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.12.005 · Cited by 107
“Here, genetic experiments in animal models of tumorigenesis will be invaluable in teasing apart the contribution of tRNA synthesis to the oncogenic effects of factors such as TORC1, Ras, Myc, p53 and Rb. 2.”
BackgroundInfluentialMetabolic Plasticity of Tumor Cell Mitochondria
Cannino, G., Ciscato, F., Masgras, I., Sànchez‐Martìn, C., & Rasola, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00333 · Cited by 103
Rai, A., Greening, D. W., Xu, R., Chen, M., Suwakulsiri, W., & Simpson, R. J. (2021) · Communications Biology · doi:10.1038/s42003-021-01882-z · Cited by 97
Lloyd, M. R., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2947 · Cited by 101
Spatial dynamics of TRAIL death receptors in cancer cells
Twomey, J. D., Kim, S.-R., Zhao, L., Bozza, W. P., & Zhang, B. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.001 · Cited by 105
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Wang, J., Hu, K., Guo, J., Cheng, F., Lv, J., Jiang, W., Lu, W., Liu, J., Pang, X., & Liu, M. (2016) · Nature Communications · doi:10.1038/ncomms11363 · Cited by 96
“However, 30 years after its characterization, mutant KRAS still poses a significant therapeutic challenge and is associated with poor prognosis and resistance to existing therapies 7,8 .”
Septin Mutations in Human Cancers
Angelis, D., & Spiliotis, E. T. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00122 · Cited by 107
“These mutational hotspots comprise amino acids, which are key for the hydrolysis of GTP, and have been developed as prognostic markers and targets for anti-cancer therapies (Pylayeva-Gupta et al., 2011; Chang et al., 2016; Lu et al., 2016).”
BackgroundResultInfluentialKRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
Shukla, S., Allam, U. S., Ahsan, A., Chen, G., Krishnamurthy, P. M., Marsh, K., Rumschlag, M., Shankar, S., Whitehead, C., Schipper, M., et al. (2014) · Neoplasia · doi:10.1593/neo.14184 · Cited by 96
“[1] Pylayeva-Gupta Y, Grabocka E, and Bar-Sagi D (2011).”
Advances in the treatment of neurofibromatosis-associated tumours
Lin, A. L., & Gutmann, D. H. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.144 · Cited by 99
Bouillez, A., Rajabi, H. N., Pitroda, S. P., Jin, C., Alam, M., Kharbanda, A., Tagde, A., Wong, K., & Kufe, D. W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1804 · Cited by 96
“NSCLCs that harbor an oncogenic KRAS mutation are often resistant to conventional and targeted agents (38).”
Marabese, M., Ganzinelli, M., Garassino, M. C., Shepherd, F. A., Piva, S., Caiola, E., Macerelli, M., Bettini, A., Lauricella, C., Floriani, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5607 · Cited by 101
“Point mutations occur in tumors resulting in the loss of intrinsic GTPase activity and consequently in the deregulation of cell proliferation signals [1].”
BackgroundPharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
Kang, R., Hou, W., Zhang, Q., Chen, R., Lee, Y. J., Bartlett, D. L., Lotze, M. T., Tang, D., & Zeh, H. J. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.445 · Cited by 98
RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity
Kawasaki, J., Aegerter, S., Fevurly, R. D., Mammoto, A., Mammoto, T., Şahin, M., Mably, J. D., Fishman, S. J., & Chan, J. C.-Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67084 · Cited by 99
“Discovering that RASGAPs, such as RASA1, function as negative regulators of RAS has improved our understanding of how certain oncogenic mutations allow RAS to avoid RASGAPs and remain constitutively activated (51, 52).”
Schott, C., Graab, U., Cuvelier, N., Hahn, H., & Fulda, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00131 · Cited by 90
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Aslan, M., Shahbazi, R., Ulubayram, K., & Özpolat, B. (2018) · Anticancer Research · doi:10.21873/anticanres.13026 · Cited by 96
Brandt, R., Sell, T., Lüthen, M., Uhlitz, F., Klinger, B., Riemer, P., Giesecke-Thiel, C., Schulze, S., El-Shimy, I. A., Kunkel, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10954-y · Cited by 91
Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy
Ramirez, J. A. Z., Romagnoli, G. G., & Kaneno, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118745 · Cited by 95
Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis
Zeng, T., Wang, Q., Fu, J., Lin, Q., Bi, J., Ding, W., Qiao, Y., Zhang, S., Zhao, W., Lin, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.045 · Cited by 94
“Because oncogenic mutations of Ras occur frequently in human cancers (Pylayeva-Gupta et al., 2011), we wondered whether these mutations could inhibit Nedd4-1-mediated Ras degradation.”
Tang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2603 · Cited by 91
“Suppression of FAK leads to activation of the DNA damage response in mutant KRAS NSCLC cells To characterize the effect of FAK suppression inNSCLC cells, we assessed the status of several targets of KRAS (6).”
BackgroundMartinko, A. J., Truillet, C., Julien, O., Diaz, J. E., Horlbeck, M. A., Whiteley, G., Blonder, J., Weissman, J. S., Bandyopadhyay, S., Evans, M. J., et al. (2018) · eLife · doi:10.7554/elife.31098 · Cited by 91
“Collectively, these pathways induce dramatic changes to cells including transcriptional reprogramming, promotion of cell survival, suppression of apoptosis, metabolic rewiring, promotion of proliferation, and increased cell invasiveness (Pylayeva-Gupta et al., 2011).”
BackgroundChew, T. W., Liu, X. J., Liu, L., Spitsbergen, J. M., Gong, Z., & Low, B. C. (2013) · Oncogene · doi:10.1038/onc.2013.240 · Cited by 91
“The Raf/MAPK and PI3K/Akt cascades are two such downstream effectors of RAS signaling that were largely implicated in many RAS-driven tumorigenesis (1, 4).”
BackgroundResultSalgado, C. M., Basu, D., Nikiforova, M. N., Bauer, B. S., Johnson, D., Rundell, V. L. M., Grunwaldt, L. J., & Reyes‐Múgica, M. (2014) · Pediatric and Developmental Pathology · doi:10.2350/14-10-1566-oa.1 · Cited by 91
“NRAS is a well-characterized oncogene involved in controlling key cell signaling pathways [17,18].”
BackgroundSynthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“RAS signaling through both the MAPK and PI3K-AKT-MTOR pathways has been shown to mediate anti-apoptotic signaling through downregulation of pro-apoptotic mediators and upregulation of anti-apoptotic proteins (Pylayeva-Gupta et al. 2011).”
BackgroundMartín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610957 · Cited by 88
Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer
Devi, K. P., Rajavel, T., Daglia, M., Nabavi, S. F., Bishayee, A., & Nabavi, S. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.001 · Cited by 97
Adhikari, H., & Counter, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05692-6 · Cited by 91
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 100
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A., & Lebbé, C. (2019) · Cancers · doi:10.3390/cancers11081133 · Cited by 97
RAS interaction with PI3K p110α is required for tumor-induced angiogenesis
Murillo, M. M., Zelenay, S., Nye, E., Castellano, E., Lassailly, F., Stamp, G., & Downward, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74134 · Cited by 84
“Moreover, RAS itself has proved impossible to target effectively to date (11, 12).”
RHO GTPases in cancer: known facts, open questions, and therapeutic challenges
Bustelo, X. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170531 · Cited by 88
Henry, J. R., Kaufman, M. D., Peng, S.-B., Ahn, Y. M., Caldwell, T. M., Vogeti, L., Telikepalli, H., Lu, W.-P., Hood, M. M., Rutkoski, T. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00067 · Cited by 84
Yang, K., Li, Y., Lian, G., Lin, H., Shang, C., Zeng, L., Chen, S., Li, J., Huang, C., Huang, K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31248 · Cited by 88
“Once KRAS mutations occur, RAS protein is accumulated in its active conformation, leading to aberrant cellular proliferation, suppression of apoptosis and promotion of metastasis.(20) Direct suppression of KRAS mutations or applying RAS protein blocker seems like inhibiting the pancreatic cancer cell proliferation, an…”
BackgroundKRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops
Eibl, G., & Rozengurt, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.007 · Cited by 85
“This has been thought to induce and sustain activation of a multitude of downstream signaling effectors, which ultimately result in many of the phenotypic hallmarks of cancer [13,15], including unhindered proliferation, suppression of apoptotic cell death, reprogramming of the cellular energy metabolism, evasion of im…”
BackgroundOncogene-Driven Metabolic Alterations in Cancer
Min, H., & Lee, H. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.211 · Cited by 92
“TUMOr MIcrOenvIrOnMenT-MeDIaTeD MeTabOlIc rePrOgraMMIng In cancer The interaction between tumors and the surrounding stromal cells that make up the tumor microenvironment has been known to be implicated in cancer development and progression (Quail and Joyce, 2013).”
BackgroundThe role of E3 ubiquitin ligases in the development and progression of glioblastoma
Humphreys, L. M., Smith, P., Chen, Z., Fouad, S., & D’Angiolella, V. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00696-6 · Cited by 94
“As one of the most commonly mutated pathways in human cancer, it translates extracellular signals into cellular phenotypes such as proliferation, differentiation, migration and invasion [161].”
BackgroundLiposome-based diagnostic and therapeutic applications for pancreatic cancer
Raza, F., Evans, L., Motallebi, M., Zafar, H., Pereira‐Silva, M., Saleem, K., Peixoto, D., Rahdar, A., Sharifi, E., Veiga, F., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.013 · Cited by 92
Birkeland, E., Wik, E., Mjøs, S., Hoivik, E. A., Trovik, J., Werner, H. M. J., Kusonmano, K., Petersen, K., Raeder, M. B., Holst, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.477 · Cited by 84
“Alterations of KRAS are considered to be an important biological factor in several cancer types (Pylayeva-Gupta et al, 2011).”
BackgroundYan, M., Li, X., Tong, D., Han, C., Zhao, R., He, Y., & Jin, X. (2016) · Oncology Reports · doi:10.3892/or.2016.4767 · Cited by 88
“The Ras pathway is one of the most commonly deregulated pathways in human cancer (7), as one-third of human cancers have been observed to harbor high frequency of mutational activation of Ras proteins (8).”
Targeting drivers of melanoma with synthetic small molecules and phytochemicals
Strickland, L. R., Pal, H. C., Elmets, C. A., & Afaq, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.016 · Cited by 91
“GAPs accelerate RAS-mediated GTP hydrolysis and lead to inactivation of RAS [16].”
BackgroundImplication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Baer, R., Cintas, C., Therville, N., & Guillermet‐Guibert, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.001 · Cited by 90
Rowald, K., Mantovan, M., Passos, J., Buccitelli, C., Mardin, B. R., Korbel, J. O., Jechlinger, M., & Sotillo, R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.048 · Cited by 84
“Pro-survival signals downstream of Kras (Pylayeva-Gupta et al., 2011) and Her2 (Moasser, 2007) as well as supporting signals from the microenvironment (Radisky, 2012) might thereby promote cell cycle progression.”
BackgroundMelanogenesis and the Targeted Therapy of Melanoma
Li, C., Kuai, L., Cui, R., & Miao, X. (2022) · Biomolecules · doi:10.3390/biom12121874 · Cited by 101
Al-Rohil, R. N., Tarasen, A. J., Carlson, J. A., Wang, K., Johnson, A., Yelensky, R., Lipson, D., Elvin, J. A., Vergilio, J., Ali, S. M., et al. (2015) · Cancer · doi:10.1002/cncr.29738 · Cited by 89
“In the current series of cSCC, 8% of the cases featured HRAS mutations, a finding that is similar to the frequency of this alteration listed in the COSMIC database.(32,36) The frequency of HRAS alterations appears to be enriched to >40% among cSCCs that develop in”
ResultKazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H. R., Beato, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3399 · Cited by 81
“When the tumors reached approximately 200 mm(3), the animals were randomized to the following treatment groups: (1) vehicle control group (40% 2-hydroxypropyl-β-cyclodextrin [Sigma] wt/vol in sterile water), administered once daily via 100-μL intraperitoneal injections, and (2) FGTI-2734 group, with FGTI-2734 administ…”
BackgroundMethodInfluentialLanfredini, S., Thapa, A., & O’Neill, E. E. (2019) · Biochemical Society Transactions · doi:10.1042/bst20170521 · Cited by 88
Singha, P., Pandeswara, S., Venkatachalam, M. A., & Saikumar, P. (2013) · Cell Death and Disease · doi:10.1038/cddis.2012.192 · Cited by 83
Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis
King, P. D., Lubeck, B. A., & Lapinski, P. E. (2013) · Science Signaling · doi:10.1126/scisignal.2003669 · Cited by 78
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.079 · Cited by 80
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
Yu, B., Swatkoski, S., Holly, A., Lee, L. C., Giroux, V., Lee, C.-S., Hsu, D., Smith, J. L., Yuen, G., Yue, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415569112 · Cited by 76
“KRAS mutations occur in ∼60% of pancreatic ductal carcinomas, 26% of lung adenocarcinomas, and 45% of colorectal carcinomas, as well as a significant fraction of ovarian, endometrial, and biliary track cancers (2, 3).”
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 76
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 80
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.